Under pressure to widen global access to Covid-19 vaccines, the Biden administration plans to invest billions of dollars to expand U.S. manufacturing capacity with an eye toward producing at least 1 billion doses annually no later than the second half of 2022.
But the effort was greeted with mixed reactions. Patient advocates lauded the move, but at the same time, they lamented such a step was not taken months ago and questioned some of the details.
“Late is definitely better than never,” said Jayasree Iyer, who heads the Access to Medicines Foundation, which tracks moves by governments and companies to provide medication to low-income countries. “But so much more may have been accomplished if such steps were taken sooner.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
